Small Molecules
19 November 2019
Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure18 November 2019
Medivir reports last patient recruited to the phase Ia study of MIV-818 in liver cancer patients and initial dose determined for phase Ib16 November 2019
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint15 November 2019
Qtrilmet approved in the EU for the treatment of type-2 diabetes14 November 2019
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder14 November 2019
US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review13 November 2019
Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program13 November 2019
EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform13 November 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients13 November 2019
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial13 November 2019
Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH13 November 2019
X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM SyndromeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports